IR Insights: Introducing Dr. David Berman, Moderna’s Chief Development Officer, and Recapping Moderna’s 2026 AACR Annual Meeting Presentation on mRNA-4359

Earlier today, Moderna presented data from a Phase 1/2 study of mRNA-4359, an investigational cancer antigen therapy, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, held from April 17-22, 2026.

Watch our latest IR Insights video with Dr. David Berman, Moderna’s new Chief Development Officer, to learn more about the presentation and Dr. Berman’s journey to Moderna.

Stay tuned for more updates and follow us on LinkedIn and X to learn more about Moderna and how we’re changing the future of medicine.

Forward-Looking Statements

This post and accompanying video contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential of intismeran autogene; potential intismeran Phase 3 adjuvant melanoma data in 2026; the potential of Moderna’s expanded oncology porfolio; the safety and efficacy of mRNA-4359; the potential of mRNA-4359 in oncology; encouraging high response rates and mechanistic translational results; and future data for mRNA-4359. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this post are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this post in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this post.